Withings and Abbott Partner for Glucose Data Integration

Withings has expanded its CES 2026 announcements with a strategic partnership involving Abbott. The French health technology company revealed that users of Abbott's Lingo device will soon be able to sync their glucose monitoring data directly into the Withings ecosystem. This functionality is expected to become available in the first quarter of the year.

The Lingo device represents Abbott's entry into the over-the-counter continuous glucose monitor market, specifically targeting nondiabetic consumers interested in metabolic optimization. The partnership extends beyond simple data sharing, as Withings will also serve as a retail channel for the technology. Customers visiting the Withings US website will be able to purchase Lingo CGMs for $89 per two-sensor package.

This development aligns with Withings' broader strategy to position its devices as comprehensive health hubs. The company recently unveiled a smart scale intended to function as a 'longevity station,' highlighting a dedicated focus on metabolic health metrics such as glucose levels.

The collaboration between Withings and Abbott focuses on creating a unified health monitoring experience. By linking the two platforms, users will gain a more holistic view of their health metrics without needing to switch between multiple applications. The integration specifically targets the sharing of glucose data collected by the Lingo device.

Abbott's Lingo is designed to bridge the gap between medical-grade monitoring and consumer wellness. It caters to individuals who are not diabetic but wish to understand how their diet and lifestyle affect their blood sugar levels. By making this data available within the Withings app, the companies aim to provide deeper insights into metabolic health.

The timeline for this integration is set for the first quarter of the year. This rapid deployment suggests that the technical groundwork for data sharing was likely established prior to the public announcement. Users can expect a seamless connection once the update rolls out.

In addition to software integration, Withings will function as a direct distributor for Abbott's technology. This move simplifies the purchasing process for existing Withings customers who wish to add glucose monitoring to their health tracking regimen.

The devices will be available for purchase on the official Withings US website. The pricing structure is straightforward:

• Cost: $89 for the purchase
• Contents: Two sensors

This retail strategy allows Withings to capture revenue from hardware sales while enhancing the value proposition of its software ecosystem. For consumers, it offers a one-stop shop for acquiring and integrating advanced health monitoring tools into their daily routine.

This partnership announcement was made during Withings' presence at CES 2026. It was revealed shortly after the company showcased other new hardware, indicating a busy schedule of product launches and strategic reveals for the health tech firm.

Earlier in the technology conference, Withings introduced a new smart scale. A notable aspect of this device is the company's ambition to rebrand it as a 'longevity station.' This terminology reflects a shift in the industry toward viewing home health devices not just as measurement tools, but as comprehensive platforms for extending healthy living.

The focus on metabolic health serves as the connecting thread between these announcements. By combining the new smart scale's capabilities with Abbott's glucose monitoring technology, Withings is building an ecosystem that addresses various facets of metabolic wellness. The integration of glucose levels is a critical component of this strategy, as it provides real-time feedback on how lifestyle choices impact the body's energy processing.